AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23815885 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinics without non-physician providers)
Number of subjects: 2254
Study 21640062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride sustained slow‐releasing device (FSSRD)
Number of subjects: 65
Study 21640062 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (PD)
Number of subjects: 65
Study 19626443 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n = 37)
Number of subjects: 75
Study 19626443 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 38)
Number of subjects: 75
Study 16686813 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making training for opioid treatment (n=22)
Number of subjects: 45
Study 16686813 — intervention group
Group type: COMPARATOR
Intervention: Written educational materials (control, n=23)
Number of subjects: 45
Study 15599321 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 6
Study 11406838 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (osteoporosis drug)
Number of subjects: 0
Study 11406838 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal mixture model
Number of subjects: 0
Study 11406838 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation studies
Number of subjects: 0
Study 10805853 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with the help of the external straightener
Number of subjects: 200
Study 10805853 — intervention group
Group type: COMPARATOR
Intervention: Traditional colonoscopy methods (manual abdominal compression)
Number of subjects: 200
Study 8857860 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection (2 cm margin)
Number of subjects: 152
Study 8857860 — intervention group
Group type: COMPARATOR
Intervention: Extended resection (12 cm margin)
Number of subjects: 152
Study 8857860 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 1 (microscopically normal tissue)
Number of subjects: 152
Study 8857860 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 2 (nonspecific changes)
Number of subjects: 152
Study 8857860 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 3 (suggestive but not diagnostic for CD)
Number of subjects: 152
Study 8857860 — intervention group
Group type: EXPERIMENTAL
Intervention: Category 4 (diagnostic for CD)
Number of subjects: 152
Study 1900313 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) 100 mg
Number of subjects: 21
Study 1900313 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 1.5 million U
Number of subjects: 21
Study 1900313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6401594 — intervention group
Group type: COMPARATOR
Intervention: Melphalan alone
Number of subjects: 233
Study 6401594 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan plus hexamethylmelamine
Number of subjects: 233
Study 6401594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus cyclophosphamide
Number of subjects: 233
Study 31972104 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses with good perception levels of risk factors for phlebitis
Number of subjects: 199
Study 31972104 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical area of nurses
Number of subjects: 199
Study 30891820 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 (1100 mg)
Number of subjects: 25
Study 30891820 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 (1000 mg/day)
Number of subjects: 25
Study 30891820 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 with atosiban
Number of subjects: 25
Study 30891820 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 with betamethasone
Number of subjects: 25
Study 30891820 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 with nifedipine
Number of subjects: 25
Study 29977072 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 156
Study 29977072 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 156
Study 27267504 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Dynamic Therapy (IDT)
Number of subjects: 38
Study 27267504 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 38
Study 25200271 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive prone lumbar extension exercises
Number of subjects: 32
Study 25200271 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained prone lumbar extension exercises
Number of subjects: 32
Study 25200271 — intervention group
Group type: COMPARATOR
Intervention: Comparison between sustained and repetitive prone lumbar extension exercises
Number of subjects: 32
Study 22849818 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella (5g, tablets)
Number of subjects: 51
Study 22849818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 20618358 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR training (BFR-T)
Number of subjects: 10
Study 20618358 — intervention group
Group type: COMPARATOR
Intervention: Non-BFR training (CON-T)
Number of subjects: 10
Study 17197122 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant postoperative radiochemotherapy with Mitomycin C and Bleomycin (CRT)
Number of subjects: 114
Study 17197122 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (RT)
Number of subjects: 114
Study 16157935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 273
Study 16157935 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (no chemotherapy)
Number of subjects: 273
Study 16157935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and Supportive care
Number of subjects: 273
Study 12699097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxacillin perioperatively (prospective group)
Number of subjects: 197
Study 12699097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 2 g intravenously (randomised study)
Number of subjects: 197
Study 12699097 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (randomised study)
Number of subjects: 197
Study 12699097 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure of primary normal healing
Number of subjects: 197
Study 9867725 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of ACI-TIPI
Number of subjects: 10689
Study 7639972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 500 mg six times daily
Number of subjects: 159
Study 7639972 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir 5 mg/kg once daily infused over 1 h
Number of subjects: 159
Study 2502256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol given in doses that reduced the resting pulse rate by 25%
Number of subjects: 50
Study 2502256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31506919 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anaesthesia (CEGA)
Number of subjects: 58
Study 31234645 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus paclitaxel
Number of subjects: 39
Study 31234645 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 39
Study 29258111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin-based triple therapy (EAC group)
Number of subjects: 0
Study 29258111 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-based triple therapy (EAM group)
Number of subjects: 0
Study 25959199 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium (BPS) with RAS inhibitor (120 μg/day)
Number of subjects: 26
Study 25959199 — intervention group
Group type: COMPARATOR
Intervention: Control group (RAS inhibitor only)
Number of subjects: 26
Study 23631971 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix/crib treatment
Number of subjects: 28
Study 23631971 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 28
Study 21435823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral minimally invasive hip surgery (ALMIS)
Number of subjects: 79
Study 21435823 — intervention group
Group type: COMPARATOR
Intervention: Standard lateral transgluteal Hardinge approach
Number of subjects: 79
Study 19392993 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic bacteria (Bifidobacterium bifidum, Bifidobacterium lactis, Lactococcus lactis; Ecologic Panda) administered prenatally to mothers and to their offspring for the first 12 months of life
Number of subjects: 102
Study 19392993 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic bacteria (Bifidobacterium bifidum, Bifidobacterium lactis, Lactococcus lactis; Ecologic Panda)
Number of subjects: 102
Study 19392993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 16877628 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out method
Number of subjects: 152
Study 16877628 — intervention group
Group type: COMPARATOR
Intervention: Opt-in method
Number of subjects: 152
Study 15474245 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg 17beta-estradiol with 10 mg dydrogesterone (HRT)
Number of subjects: 25
Study 15474245 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg 17beta-estradiol without dydrogesterone (ERT)
Number of subjects: 25
Study 15474245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11302275 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard mail intervention
Number of subjects: 0
Study 11302275 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard mail program combined with personalized written feedback
Number of subjects: 0
Study 11302275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9311477 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 450
Study 9311477 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 4 units of blood products
Number of subjects: 450
Study 9311477 — intervention group
Group type: COMPARATOR
Intervention: No transfusion with portal infusion of chemotherapy
Number of subjects: 450
Study 7506184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100mg
Number of subjects: 30
Study 7506184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200mg
Number of subjects: 30
Study 7506184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2447687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1,200 mg/day
Number of subjects: 6
Study 2447687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg/day
Number of subjects: 6
Study 2447687 — intervention group
Group type: COMPARATOR
Intervention: No H2-receptor antagonist (control)
Number of subjects: 6
Study 30179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily from a month before surgery to 12 months after surgery)
Number of subjects: 16
Study 30179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (20 μg of teriparatide daily and 60 mg denosumab every 6 months)
Number of subjects: 16
Study 30179720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 16
Study 28316464 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of ropivacaine 1%
Number of subjects: 0
Study 28316464 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of ropivacaine 1%
Number of subjects: 0
Study 28316464 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of ropivacaine 1%
Number of subjects: 0
Study 26096609 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 475
Study 23801735 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus-deep brain stimulation (DBS)
Number of subjects: 68
Study 23801735 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 68
Study 20370943 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula (n 146)
Number of subjects: 474
Study 20370943 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control group, n 169)
Number of subjects: 474
Study 20370943 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed group (n 159)
Number of subjects: 474
Study 17637612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 185
Study 17637612 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 185
Study 16832128 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol injections in the area of neovascularization
Number of subjects: 33
Study 16832128 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine/epinephrine injections (control group)
Number of subjects: 33
Study 16832128 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol injections (after crossover for control group)
Number of subjects: 33
Study 16832128 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol injections (treatment group)
Number of subjects: 33
Study 12975389 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction through energy restriction, increased physical activity, or both
Number of subjects: 4874
Study 12975389 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction >5 kg
Number of subjects: 4874
Study 12975389 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction in populations taking antihypertensive drugs
Number of subjects: 4874
Study 12975389 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss per kilogram
Number of subjects: 4874
Study 11104175 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated presentation of text passages
Number of subjects: 0
Study 11104175 — intervention group
Group type: EXPERIMENTAL
Intervention: Varying the schedule of presentations and tests
Number of subjects: 0
Study 11104175 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning participants against basing recall on previous efforts
Number of subjects: 0
Study 11104175 — intervention group
Group type: EXPERIMENTAL
Intervention: Making each presentation more distinctive
Number of subjects: 0
Study 11104175 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing attention to areas needing further learning by tallying omissions and errors
Number of subjects: 0
Study 8889459 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 3 mg oral pH-modified release budesonide (BUD)
Number of subjects: 67
Study 8889459 — intervention group
Group type: COMPARATOR
Intervention: 6-methylprednisolone (MPred)
Number of subjects: 67
Study 1894864 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty followed by a 30‐min intracoronary infusion of Fluosol at 40 ml/min
Number of subjects: 26
Study 1894864 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty alone
Number of subjects: 26
Study 6189412 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparindihydroergotamine s.c.
Number of subjects: 60
Study 6189412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 6% 500 ml
Number of subjects: 60
Study 6189412 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 60
Study 28958152 — intervention group
Group type: EXPERIMENTAL
Intervention: Omron HEM907™ (arm)
Number of subjects: 48
Study 28958152 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlife WatchBPhome (arm)
Number of subjects: 48
Study 28958152 — intervention group
Group type: EXPERIMENTAL
Intervention: Average of three consecutive measurements
Number of subjects: 48
Study 27471039 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant and zinc supplements
Number of subjects: 4124
Study 27471039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4124
Study 24054870 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact LigaSure device
Number of subjects: 80
Study 24054870 — intervention group
Group type: COMPARATOR
Intervention: Endo GIA Stapler
Number of subjects: 80
Study 22111942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg/month)
Number of subjects: 41
Study 22111942 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study 20797478 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry beverage (50 g freeze-dried strawberries approximately 3 cups fresh strawberries)
Number of subjects: 27
Study 20797478 — intervention group
Group type: COMPARATOR
Intervention: Control (4 cups of water)
Number of subjects: 27
Study 18845958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime juice (100%)
Number of subjects: 47
Study 18845958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime juice (25%, 50%, or undiluted)
Number of subjects: 47
Study 18845958 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 47
Study 16879079 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy and interpersonal psychotherapy
Number of subjects: 95
Study 16879079 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive sleep interventions (suggested)
Number of subjects: 95
Study 14511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality system for multimodal assessment of cognitive ability
Number of subjects: 0
Study 10735974 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐Technegas and 99mTc‐macro‐aggregated human albumin used for ventilation and perfusion imaging in emphysematous patients.
Number of subjects: 16
Study 10735974 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 16
Study 8922768 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg.kg‐1
Number of subjects: 0
Study 8922768 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1
Number of subjects: 0
Study 8922768 — intervention group
Group type: COMPARATOR
Intervention: No anticholinesterase (Control Group 1)
Number of subjects: 0
Study 1313951 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (mean of 11.2 g per day) for 3 months
Number of subjects: 27
Study 1313951 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 27
Study 2985675 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization (n = 6)
Number of subjects: 54
Study 2985675 — intervention group
Group type: COMPARATOR
Intervention: Control patients (n = 6)
Number of subjects: 54
Study 2985675 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not undergo recanalization (n = 7)
Number of subjects: 54
Study 30125001 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Fit Blue Participants (N = 248)
Number of subjects: 359
Study 30125001 — intervention group
Group type: COMPARATOR
Intervention: Non-Randomized Cohort (N = 111)
Number of subjects: 359
Study 29182948 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart's sonata in D major for two pianos K448 for 2h/day for 2 weeks
Number of subjects: 19
Study 29182948 — intervention group
Group type: EXPERIMENTAL
Intervention: Set of Mozart's compositions
Number of subjects: 19
Study 26660907 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy condition under low cognitive load
Number of subjects: 0
Study 26660907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger condition
Number of subjects: 0
Study 26660907 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy condition
Number of subjects: 0
Study 26660907 — intervention group
Group type: COMPARATOR
Intervention: High and low cognitive load conditions
Number of subjects: 0
Study 24606626 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented Numerical
Number of subjects: 41
Study 24606626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-oriented Numerical
Number of subjects: 41
Study 24606626 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented Comment
Number of subjects: 41
Study 24606626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-oriented Comment
Number of subjects: 41
Study 22905985 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medicine approach (journaling, yoga breathing instruction, nutritional manipulation and supplementation)
Number of subjects: 20
Study 22905985 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (control group)
Number of subjects: 20
Study 20942288 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 17679567 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg)
Number of subjects: 24
Study 17679567 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 24
Study 17679567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16239176 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity at midlife at least twice a week
Number of subjects: 1449
Study 11089753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (0.5 or 2.0 microg.kg.min)
Number of subjects: 286
Study 11089753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 9116274 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT (daunorubicin, cytarabine, thioguanine)
Number of subjects: 1857
Study 9116274 — intervention group
Group type: COMPARATOR
Intervention: ADE (daunorubicin, cytarabine, etoposide)
Number of subjects: 1857
Study 9116274 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT
Number of subjects: 1857
Study 9116274 — intervention group
Group type: COMPARATOR
Intervention: ADE
Number of subjects: 1857
Study 8436062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (50-60 mg p.o.)
Number of subjects: 7
Study 8436062 — intervention group
Group type: EXPERIMENTAL
Intervention: One eye closed
Number of subjects: 7
Study 8436062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighting intensity increase
Number of subjects: 7
Study 3767388 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (B) - 8 mg/body on day 1, 4 mg/body on days 2 and 3
Number of subjects: 56
Study 3767388 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) - 1,000 mg/body on day 1, 500 mg/body on days 2 and 3
Number of subjects: 56
Study 3767388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 56
Study 30130430 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching for 9 months
Number of subjects: 192
Study 30130430 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 192